Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462156 | 0.93 | EGFR (0.52) | EGFR | |
| SCHEMBL5465063 | 0.92 | ABL1 (0.51) | EGFR | |
| SCHEMBL5463571 | 0.92 | EGFR (0.50) | EGFRERBB2 | |
| SCHEMBL5471305 | 0.92 | EGFR (0.57) | EGFR | |
| SCHEMBL5475292 | 0.91 | EGFR (0.58) | EGFRERBB2RETERBB4 | |
| SCHEMBL5465190 | 0.91 | EGFR (0.60) | EGFR | |
| SCHEMBL5471146 | 0.90 | EGFR (0.49) | EGFRERBB2RETERBB4 | |
| SCHEMBL5462233 | 0.90 | ABL1 (0.49) | EGFR | |
| SCHEMBL5472870 | 0.90 | EGFR (0.56) | EGFR | |
| SCHEMBL5463018 | 0.90 | ABL1 (0.52) | EGFRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | EGFR 4385/4885ERBB2 4281/4885RET 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.